Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting.

Xuejiao YinYi LiuJianai SunHongyan TongHaitao MengLiang-Shun You

Published in: Therapeutic advances in chronic disease (2023)

This article provides an overview of the latest advances in BsAbs immunotherapy for refractory and relapsed MM and highlights significant findings from the 2022 ASH annual meeting.

Keyphrases

multiple myeloma
municipal solid waste
sewage sludge
acute lymphoblastic leukemia
acute myeloid leukemia
combination therapy
risk assessment